Matthijs Janssen

Matthijs Janssen, MD, PhD, joined Olatec’s Drug Development Team in February 2016 and became a member of the Clinical Advisory Board in October 2019. In collaboration with Dr. Tim Jansen, Dr. Matthijs Janssen has been contributing leading expertise in all areas of Olatec’s clinical program in gout, including serving as Investigator in the first and second clinical trials with dapansutrile for acute gout flares. Dr. Janssen has over 30 years of experience in rheumatological disease and specializes in treatment modalities and co-morbidities of gout, research in gastro- intestinal damage resulting from use of NSAIDs, and clinical trials in gout and reactive arthritis. Dr. Janssen is currently a rheumatologist at VieCuri Medisch Centrum/Northern Limburg, Venlo, the Netherlands. From 1992 – 2017, Dr. Janssen was a rheumatologist at Rijnstate Hospital in Arnhem, the Netherlands, where he trained approximately 40 rheumatologists. Dr. Janssen chairs the creation of the Dutch Guidelines on gout disease. He has authored publications on gout in The Lancet, Archives of Internal Medicine and in the Annals of Rheumatic Diseases and (co-) authored more than 120 national and international PubMed publications. Dr. Janssen also serves as a reviewer of many Rheumatology Journals. Dr. Janssen studied at the University of Groningen, the Netherlands and was trained in Internal Medicine (Medical Spectrum Twente; Enschede) and Rheumatology (Leiden University Medical Centre; Leiden). He received his PhD in May 1994.